



Immunisation recommendations for people with certain medical risk conditions

This table provides a high-level overview of vaccination recommendations for people with medical risk factors and the current funding status. This does not include advice about vaccine doses that could be considered if an individual risk–benefit assessment identifies a strong preference for vaccination. For specific details about each vaccine, including doses and minimum intervals, refer to the relevant chapter of the [Australian Immunisation Handbook](#).

The [National Immunisation Program \(NIP\) Schedule](#) is updated periodically and is available on the Department of Health and Aged Care immunisation website. Contact your state or territory health department for further information on any additional immunisation programs specific to your jurisdiction. COVID-19 and mpox vaccines are funded under emergency measures. RSV monoclonal antibody may be funded under state and territory programs.

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Cardiac disease	Congenital heart disease	R (F)	R (F)	R (NF)	R (NF) ^d	R (F) ^e	NR	NR	NR	NR	NR	NR	NR
	Congestive heart failure	R (F)	R (F)	R (NF)	NR	R (F) ^e	NR	NR	NR	NR	NR	NR	NR
	Coronary artery disease	R (F)	R (F)	R (NF)	NR	R (F) ^e	NR	NR	NR	NR	NR	NR	NR
Chronic respiratory conditions	Suppurative lung disease	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
	Bronchiectasis	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR

ATAGI = Australian Technical Advisory Group on Immunisation; Hib = *Haemophilus influenzae* type b; HPV = human papillomavirus; RSV = respiratory syncytial virus

NR = not recommended by ATAGI (white shading); R (F) = recommended by ATAGI and funded under the NIP or emergency measures (green shading); R (NF) = recommended but not funded (purple shading)

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

d Hemodynamically significant congenital heart disease only.

e Funded under the NIP for children aged <5 years only.

See the [Australian Immunisation Handbook](#) for more details.

Last updated: August 2026

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Chronic respiratory conditions	Cystic fibrosis	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	NR	NR	NR
	Chronic obstructive pulmonary disease and chronic emphysema	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
	Severe asthma (requiring frequent medical consultations or the use of multiple medicines)	R (F)	R (F)	R (NF)	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
	Chronic lung disease in preterm infants	NR	NR	NR	R (NF) ^f	R (F)	NR	NR	NR	NR	NR	NR	NR
	Interstitial and fibrotic lung disease	NR	NR	NR	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
Immunocompromising conditions	Immunosuppressive therapy	R (F)	R (F) ^g	R (NF)	R (NF) ^h	R (NF)	NR	NR	NR	NR	R (F)	R (F) ^g	NR
	Inborn errors of immunity, including primary immunodeficiency disorders ⁱ	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	R (F)	R (F)	NR
	Solid organ transplant	R (F)	R (F)	R (NF)	R (NF)	R (F)	NR	NR	R (NF) ^j	R (NF)	R (F)	R (F)	NR
	Haematopoietic stem cell transplant	R (F)	R (F)	R (NF)	R (NF)	R (F)	R (NF)	R (NF)	NR	R (NF)	R (F)	R (F)	NR
	CAR-T cell therapy	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	R (F)	NR

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

f Chronic lung disease requiring ongoing oxygen or respiratory support.

g Funded under the NIP for B- and T-cell targeted monoclonal antibody therapies, some conventional immunosuppressive agents, some biologic therapies, immunomodulatory drugs, oral small molecule targeted therapies, immunosuppressive therapies to prevent organ rejection and some interleukin inhibitors. For more detail refer to the [Australian Immunisation Handbook](#).

h Significant immunosuppression equivalent to conditions or treatments listed in the RSV chapter.

i Specific disease-based recommendations and funding may vary depending on the type of inborn error of immunity and which part of the immune system is affected. For more detail refer to the [Australian Immunisation Handbook](#).

j Liver transplant recipients.

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Immunocompromising conditions	Non-haematological malignancies receiving chemotherapy or radiotherapy (currently or anticipated)	R (F)	R (F) ^k	R (NF)	R (NF)	R (NF)	NR	NR	NR	NR	R (F)	R (F) ^k	NR
	Haematological malignancy	R (F)	R (F) ^l	R (NF)	R (NF)	R (F)	NR	NR	NR	NR	R (F)	R (F)	NR
	HIV infection	R (F)	R (F) ^m	R (NF)	R (NF) ⁿ	R (F)	NR	R (NF)	NR	R (NF)	R (F) ^o	R (F) ^m	R (NF) ^p
	Asplenia or splenic dysfunction	R (F)	R (F)	R (NF)	NR	R (F)	R (F)	R (F)	NR	NR	NR	NR	NR
	Complement deficiency/ complement inhibitor treatment	NR	NR	NR	NR	NR	NR	R (F)	NR	NR	NR	R (NF)	NR
Haematological disorder	Sickle cell disease or other haemoglobinopathies	R (F)	R (F)	R (NF)	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic metabolic disorder	Type 1 or 2 diabetes	R (F)	R (F)	R (NF)	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
	Amino acid disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Carbohydrate disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Cholesterol biosynthesis disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Fatty acid oxidation defects	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Lactic acidosis	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Mitochondrial disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

k Funded under the NIP for people with non-haematological cancers receiving chemotherapy only (i.e. not radiotherapy alone).

l Funded under the NIP for those treated with B- and T-cell targeted therapies and immunomodulatory drugs. For more detail refer to the [Australian Immunisation Handbook](#).

m Funded under the NIP for HIV infection with a CD4+ cell count <200/μL.

n RSV monoclonal antibody is recommended for infants and children who have CD4+ count associated with severe immunocompromise (CD4+ cell count: <750/uL for infants aged <12 months and <500/uL for children aged ≥12 to <24 months).

o Funded under the NIP for people aged <26 years only.

p Mpox vaccination is recommended for people living with HIV if they are at risk of mpox exposure.

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Chronic metabolic disorder	Organic acid disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Urea cycle disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Vitamin/cofactor disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Porphyrias	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Chronic kidney disease	Chronic renal impairment – eGFR <30 mL/min (stage 4 or 5 disease)	R (F)	R (F)	R (NF)	NR	R (F) ^q	NR	NR	NR	R (NF)	NR	R (F) ^q	NR
	Relapsing or persistent nephrotic syndrome	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Chronic neurological condition	Hereditary and degenerative CNS diseases	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
	Seizure disorders	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Spinal cord injuries	R (F)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Neuromuscular disorders	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
	Conditions that impair respiratory or airway function	R (F)	R (F)	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR
Proven or presumptive cerebrospinal fluid leak	Cochlear implants	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
	Intracranial shunts	NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

q Funded under the NIP for eGFR <15 mL/min only (including patients on dialysis).

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Chronic liver disease	Conditions with progressive deterioration of liver function for more than 6 months, including cirrhosis and other advanced liver diseases	R (NF)	R (F)	R (NF)	NR	R (F)	NR	NR	R (NF)	R (NF)	NR	NR	NR
Obesity	Body mass index ≥30 kg per m ²	R (NF)	R (F)	R (NF)	NR	NR	NR	NR	NR	NR	NR	NR	NR
Chromosomal abnormality	Trisomy 21 or another genetic condition that increases the risk of severe disease	R (NF)	R (F)	NR	R (NF)	R (F) ^e	NR	NR	NR	NR	NR	NR	NR
Developmental disability		NR	NR	NR	NR	NR	NR	NR	R (NF)	R (NF)	NR	NR	NR
Born to mothers who are surface antigen positive (hep B)		NR	NR	NR	NR	NR	NR	NR	NR	R (NF)	NR	NR	NR
Born to mothers who received anti-CD20 therapies (such as rituximab) during pregnancy		NR	NR	NR	R (NF)	R (NF)	NR	NR	NR	NR	NR	NR	NR
Prematurity	<37 weeks	R (F)	NR	NR	R (NF) (<32 weeks)	R (F) ^e (<28 weeks)	NR	NR	NR	R (NF) (<32 weeks) ^r	NR	NR	NR
Previous episode of severe disease (antigen-specific)		NR	NR	NR	NR	R (F)	NR	NR	NR	NR	NR	NR	NR
Receipt of blood products		NR	NR	NR	R (NF) ^s	NR	NR	NR	NR	R (NF)	NR	NR	NR
Medication use	Long-term aspirin therapy in children aged 5–10 years	R (F)	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

e Funded under the NIP for children aged <5 years only.

r Includes low-birthweight infants (<2000 g), regardless of gestational age.

s For infants who have undergone exchange transfusion at birth.

Risk condition		Influenza ^a	COVID-19 ^a	RSV (older adults) ^a	RSV (infants and young children) ^b	Pneumococcal ^c	Hib	Meningococcal	Hepatitis A	Hepatitis B	HPV	Zoster (shingles)	Mpox
Other substance use	Harmful use of alcohol ^t	R (NF)	NR	NR	NR	R (NF)	NR	NR	NR	NR	NR	NR	NR
	Smoking (current or in the immediate past)	R (NF)	NR	NR	NR	R (NF)	NR	R (NF) ^u	NR	NR	NR	NR	NR
	Intravenous drug use	NR	NR	NR	NR	NR	NR	NR	R (NF)	R (NF)	NR	NR	NR

a These vaccines are recommended for people with certain medical conditions. Similar conditions to those indicated may be included based on clinical judgement. Influenza (aged ≥6 months), RSV (aged ≥60 years) and COVID-19 (aged ≥18 years for severe immunocompromise, aged ≥50 years for Aboriginal and Torres Strait Islander adults and aged ≥65 years for non-Indigenous adults).

b RSV monoclonal antibody is recommended for children <24 months of age with certain medical conditions, irrespective of whether their mother received an RSV vaccine during pregnancy. It may be funded under state and territory programs.

c Pneumococcal vaccines are recommended for people with certain medical conditions. Cardiac and respiratory conditions that are similar to those indicated may be included based on clinical judgement.

t Defined as the consumption of on average ≥100 g of alcohol (10 Australian standard drinks) per week or ≥40 g of alcohol (4 Australian standard drinks).

u Recommended for smokers aged <25 years.